Durvalumab vs Trastuzumab

Durvalumab vs Trastuzumab: Overview

This comparison examines the pharmacological differences between Durvalumab and Trastuzumab.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Trastuzumab — 28 days.

Chemical Properties

Type: Durvalumab — Antibody; Trastuzumab — Antibody.